Orchestra BioMed said yesterday that it received the CE Mark for its Moderato implantable pulse generator system for BackBeat cardiac neuromodulation therapy (CNT), just nine days after naming a new chief medical officer. BackBeat therapy is a bioelectronic treatment designed to lower blood pressure while modulating the autonomic nervous system. The Moderato implantable device is designed to deliver BackBeat CNT and provide standard pacemaker functions.
Orchestra BioMed wins CE Mark for BackBeat hypertension neurostim, names CMO
By Michael Tattory|
2019-09-10T14:43:13-04:00
September 5th, 2019|News|Comments Off on Orchestra BioMed wins CE Mark for BackBeat hypertension neurostim, names CMO